Literature DB >> 12438307

E2F proteins regulate MYCN expression in neuroblastomas.

Verena Strieder1, Werner Lutz.   

Abstract

Amplification of the MYCN gene, resulting in overexpression of MYCN, distinguishes a subset of neuroblastomas with poor prognosis. The transcription factors driving MYCN expression in neuroblastomas are unknown. In transient-transfection assays, E2F-1, E2F-2, and E2F-3 activate a MYCN reporter construct dependent on the presence of several putative E2F-binding sites. Using chromatin immunoprecipitation, we show that E2F-1, E2F-2, and E2F-3 bind to the proximal MYCN promoter in vivo, specifically in neuroblastoma cell lines expressing MYCN. Inhibition of E2F activity in MYCN-amplified cells by the overexpression of p16(INK4A) reduced MYCN expression. In addition, we provide evidence that E2F proteins are involved in the negative regulation of MYCN by TGF-beta and retinoic acid. These data suggest that E2F transcription factors are critical for both the full activation and the repression of MYCN in neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438307     DOI: 10.1074/jbc.M207596200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Authors:  Presha Rajbhandari; Gonzalo Lopez; Claudia Capdevila; Beatrice Salvatori; Jiyang Yu; Ruth Rodriguez-Barrueco; Daniel Martinez; Mark Yarmarkovich; Nina Weichert-Leahey; Brian J Abraham; Mariano J Alvarez; Archana Iyer; Jo Lynne Harenza; Derek Oldridge; Katleen De Preter; Jan Koster; Shahab Asgharzadeh; Robert C Seeger; Jun S Wei; Javed Khan; Jo Vandesompele; Pieter Mestdagh; Rogier Versteeg; A Thomas Look; Richard A Young; Antonio Iavarone; Anna Lasorella; Jose M Silva; John M Maris; Andrea Califano
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

2.  Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.

Authors:  Andy Chi-Lung Lee; Yu-Yin Shih; Fanfan Zhou; Tsi-Chian Chao; Hsinyu Lee; Yung-Feng Liao; Wen-Ming Hsu; Ji-Hong Hong
Journal:  J Mol Med (Berl)       Date:  2019-01-05       Impact factor: 4.599

Review 3.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

4.  The MYCN oncogene is a direct target of miR-34a.

Authors:  J S Wei; Y K Song; S Durinck; Q-R Chen; A T C Cheuk; P Tsang; Q Zhang; C J Thiele; A Slack; J Shohet; J Khan
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

5.  Expression and methylation pattern of p16 in neuroblastoma tumorigenesis.

Authors:  Safiye Aktas; Aydan Cavusoglu Celebiler; Zeynep Zadeoğlulari; Gulden Diniz; Aydanur Kargi; Nur Olgun
Journal:  Pathol Oncol Res       Date:  2009-05-23       Impact factor: 3.201

Review 6.  Energy metabolism in neuroblastoma and Wilms tumor.

Authors:  Sepideh Aminzadeh; Silvia Vidali; Wolfgang Sperl; Barbara Kofler; René G Feichtinger
Journal:  Transl Pediatr       Date:  2015-01

7.  YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.

Authors:  Grace E Coggins; Alvin Farrel; Komal S Rathi; Colin M Hayes; Laura Scolaro; Jo Lynne Rokita; John M Maris
Journal:  Cancer Res       Date:  2019-10-31       Impact factor: 12.701

8.  MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.

Authors:  Marco Lodrini; Ina Oehme; Christina Schroeder; Till Milde; Marie C Schier; Annette Kopp-Schneider; Johannes H Schulte; Matthias Fischer; Katleen De Preter; Filip Pattyn; Mirco Castoldi; Martina U Muckenthaler; Andreas E Kulozik; Frank Westermann; Olaf Witt; Hedwig E Deubzer
Journal:  Nucleic Acids Res       Date:  2013-04-26       Impact factor: 16.971

9.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.

Authors:  Frank Westermann; Daniel Muth; Axel Benner; Tobias Bauer; Kai-Oliver Henrich; André Oberthuer; Benedikt Brors; Tim Beissbarth; Jo Vandesompele; Filip Pattyn; Barbara Hero; Rainer König; Matthias Fischer; Manfred Schwab
Journal:  Genome Biol       Date:  2008-10-13       Impact factor: 13.583

10.  Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression.

Authors:  R Carter; D Mullassery; V See; S Theocharatos; B Pizer; P D Losty; E Jesudason; D J Moss
Journal:  Oncogenesis       Date:  2012-08-27       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.